Email Updates

Search form

You are here

AVAC in the News

  • A major HIV prevention trial comparing a tenofovir microbicide with two forms of oral pre-exposure prophylaxis as HIV prevention methods for women is to halt investigation of oral tenofovir pre-exposure prophylaxis, the Microbicide Trials Network announced on Wednesday.

    September 29, 2011
  • A study involving women at risk of HIV infection has discontinued a comparison of daily Viread (tenofovir) pre-exposure prophylaxis (PrEP) to placebo, in light of expert projections that the clinical trial will not be able to demonstrate effectiveness, according to a September 28 Microbicide Trials Network (MTN) announcement. The Vaginal and Oral Interventions to Control the Epidemic (VOICE) study will, however, continue evaluating the safety and efficacy of another oral tablet, Truvada (tenofovir plus emtricitabine), along with a vaginal microbicide containing tenofovir.

    September 29, 2011
    POZ & AIDSMED
  • The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, today announced that it decided to stop one arm of a study involving more than 5000 women in South Africa, Zimbabwe, and Uganda. The decision followed an interim review of the ongoing trial by an independent monitoring board, which found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated.

    September 28, 2011
    ScienceInsider
  • The search for an HIV vaccine has been long and hard, and we’ve had many setbacks along the way. But two years ago we saw the first glimmer of hope when an HIV vaccine in Thailand was found to be partially effective.

    September 26, 2011
    The Star
  • Internationally, HIV vaccine research and development (R&D) funding stood at $859 million last year, $9 million less than 2009, while China increased its spending by nearly US$4 million over the same period, said the global report issued jointly by international organizations including AIDS Vaccine Advocacy Coalition (AVAC) and Intentional AIDS Vaccine Initiative.

    September 15, 2011
    China.org
  • The AIDS Vaccine 2011 conference ended Thursday in Bangkok, Thailand. While a vaccine to help end the pandemic remains elusive, scientific advances are being made. About 850 scientists, researchers and others met for four days to discuss progress on finding a vaccine to prevent HIV infection. It’s the only conference to focus exclusively on that.

    September 14, 2011
    Voice of America
  • The largest conference on AIDS vaccine development is being held in Bangkok, Thailand FROM September 12th to the 15th.  Researchers will discuss how to build on recent advances in a time of tight budgets. Organizers of the conference, known as AV-2011, say a “safe and effective AIDS vaccine would be one of the greatest public health advances ever.” But they also admit it’s one of the “greatest scientific challenges.”

    September 8, 2011
    Voice of America
  • Leading HIV prevention organizations have issued a call to action for the Department of Health and Human Services to develop a comprehensive plan of PrEP demonstration projects that identify how and where the intervention might best be used.

    August 25, 2011
    Bay Area Reporter
  • The world’s largest ongoing HIV vaccine study has been expanded to consider multiple ways a vaccine might boost immune response to the AIDS virus. The U.S. Institute of Allergy and Infectious Diseases (NIAID) is testing the safety and efficacy of a dual vaccine candidate.

    August 10, 2011
    Voice of America
  • This week the world has been looking back at 30 years of AIDS. Three decades have taken us from five young gay men in Los Angeles to 34 million men, women and children around the world living with HIV. But what about the next thirty years? Could we see an end to AIDS?

    June 9, 2011
    General
    Huffington Post

Pages